Schedule 13G ownership disclosure
Zentalis Pharmaceuticals, Inc.
Common Stock, par value $0.001 per share · CUSIP: 98943L107
Event date: 2025-09-30
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Millennium Management LLC
Shares: 902,521.00 · Class: 1.3%
- Millennium Group Management LLC
Shares: 902,521.00 · Class: 1.3%
- Israel A. Englander
Shares: 902,521.00 · Class: 1.3%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-25-099251
- Form type
- SCHEDULE 13G/A
- Filer
- MILLENNIUM MANAGEMENT LLC
- CIK
- CIK 1273087
- Filed
- Oct 14, 2025
- Reporting period
- Sep 30, 2025
- Description
- Schedule 13G beneficial ownership